ANGIOGENIC CELLS FROM HUMAN PLACENTAL PERFUSATE

• US 20090104164A1
• Filed: 09/26/2008
• Published: 04/23/2009
• Est. Priority Date: 09/26/2007
• Status: Abandoned Application

• Current Assignee: Celularity, Inc.
• Original Assignee: Celgene Cellular Therapeutics (Bristol-Myers Squibb Company)
• Inventors: Barragan, Henry Rendon, Voskinarian-Berse, Vanessa R., Zhang, Xiaokui, Kang, Lin, Heidaran, Mohammad A.
• Application Number:
  US12/239,679
• Publication Number:
  US 20090104164A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/70 Enzymes
• CPC Class Codes: C12N 5/0692 Stem cells; Progenitor cells; Precursor cells

Abstract

Provided herein are the production of vasculogenic or angiogenic cells from placental perfusate. Also provided are methods of treating an individual having a cardiac or vascular insufficiency, disease, disorder or condition comprising administering to said individual placental perfusate, placental perfusate cells, or combinations of placental perfusate or perfusate cells with placental or non-placental hematopoietic stem cells or adherent placental stem cells.

Claims

1. A method of forming vessels from a population of placental perfusate cells, comprising contacting said population of cells with conditions that promote the formation of vessels.

2. The method of claim 1, wherein said population of placental perfusate cells is total nucleated cells from placental perfusate.

3. The method of claim 1, wherein said contacting comprises contacting said cells with VEGF (50 to 200 ng/mL), TGF-β

(1 to 5 ng/mL), FGF (10 to 50 ng/mL) and one or more matrix metalloproteases (1 to 3 Unit/mL each).

4. The method of claim 1, wherein said contacting is performed in vitro.

5. The method of claim 1, wherein said contacting is performed in vivo.

6. The method of claim 1, wherein said population of placental perfusate cells comprises placental perfusate cells isolated from perfusion of a single placenta.

7. The method of claim 6, wherein said placental perfusate cells are CD34⁺ cells.

8. The method of claim 7, wherein said CD34⁺ cells are CD34^+CD45⁻

cells.

9. The method of claim 6 or claim 7, wherein said CD34⁺ cells or CD34^+CD45⁻

cells express a higher level of at least one of CD31, CXCR4 or VEGFR than an equivalent number of CD34⁺ cells from umbilical cord blood.

10. The method of claim 1, wherein said population of placental perfusate cells comprises isolated CD34⁺ cells not isolated from said perfusate.

11. The method of claim 10, wherein said CD34⁺ cells are isolated from placenta.

12. The method of claim 10, wherein said CD34⁺ cells are isolated from umbilical cord blood, placental blood, peripheral blood, or bone marrow.

13. The method of claim 10, wherein said CD34⁺ cells express a higher level of CD31, CXCR4 or VEGFR than an equivalent number of CD34⁺ cells from umbilical cord blood.

14. The method of claim 10, wherein said CD34⁺ cells are CD34⁺, CD45⁻

cells.

15. A method of treating an individual having a cardiac or vascular disease, disorder, condition or insufficiency, comprising administering human placental perfusate or human placental perfusate cells to said individual in an amount sufficient to treat said disease, disorder, condition or insufficiency.

16. The method of claim 15, wherein said disease, disorder, condition or insufficiency is peripheral vascular disease, acute or chronic myocardial infarct, cardiomyopathy, congestive or chronic heart failure, cardiovascular ischemia, hypertensive pulmonary vascular disease, peripheral arterial disease, or rheumatic heart disease.

17. The method of claim 15, wherein said placental perfusate cells are total nucleated cells from placental perfusate.

18. The method of claim 15, wherein said population of placental perfusate cells comprises placental perfusate cells isolated from perfusion of a single placenta.

19. The method of claim 18, wherein said placental perfusate cells are CD34⁺ cells.

20. The method of claim 19, wherein said CD34⁺ cells are CD34^+CD45⁻

cells.

21. The method of claim 19 or claim 20, wherein said CD34⁺ cells or CD34^+CD45⁻

cells express a higher level of at least one of CD31, CXCR4 or VEGFR than an equivalent number of CD34⁺ cells from umbilical cord blood.

22. The method of claim 15, wherein said population of placental perfusate cells comprises isolated CD34⁺ cells not isolated from said perfusate.

23. The method of claim 22, wherein said CD34⁺ cells are isolated from placenta.

24. The method of claim 22, wherein said CD34⁺ cells are isolated from umbilical cord blood, placental blood, peripheral blood, or bone marrow.

25. The method of claim 22, wherein said CD34⁺ cells express a higher level of CD31, CXCR4 or VEGFR than an equivalent number of CD34⁺ cells from umbilical cord blood.

26. The method of claim 15, wherein said placental perfusate cells are administered on a scaffold or matrix.

27. The method of claim 15, wherein said placental perfusate cells are administered intravenously.